{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:04:57Z","timestamp":1790723097225,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI020499, PI050427, PI060507"],"award-info":[{"award-number":["PI020499, PI050427, PI060507"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Plan Nacional de Drogas","award":["2005-Orden sco\/3246\/2004"],"award-info":[{"award-number":["2005-Orden sco\/3246\/2004"]}]},{"name":"SENY Fundaci\u00f3","award":["CI 2005\u20130308007"],"award-info":[{"award-number":["CI 2005\u20130308007"]}]},{"name":"Fundaci\u00f3n Marqu\u00e9s de Valdecilla","award":["API07\/011"],"award-info":[{"award-number":["API07\/011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00213-017-4763-x","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T15:41:31Z","timestamp":1509032491000},"page":"245-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-na\u00efve patients with a first-episode of non-affective psychosis"],"prefix":"10.1007","volume":"235","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5478-3376","authenticated-orcid":false,"given":"Javier","family":"V\u00e1zquez-Bourgon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"P\u00e9rez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Ortiz-Garc\u00eda de la Foz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Su\u00e1rez Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"D\u00edaz Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"4763_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/YIC.0b013e32832c2624","volume":"24","author":"K Alptekin","year":"2009","unstructured":"Alptekin K, Hafez J, Brook S et al (2009) Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 24:229\u2013238","journal-title":"Int Clin Psychopharmacol"},{"key":"4763_CR2","volume-title":"Scale for the assessment of negative symptoms (SANS)","author":"N Andreasen","year":"1983","unstructured":"Andreasen N (1983) Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa City"},{"key":"4763_CR3","volume-title":"Scale for the assessment of positive symptoms (SAPS)","author":"N Andreasen","year":"1984","unstructured":"Andreasen N (1984) Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa City"},{"key":"4763_CR4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-244X-12-78","volume":"12","author":"E Bonfioli","year":"2012","unstructured":"Bonfioli E, Berti L, Goss C et al (2012) Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomized controlled trials. BMC Psychiatry 12:78","journal-title":"BMC Psychiatry"},{"key":"4763_CR5","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","volume":"162","author":"A Breier","year":"2005","unstructured":"Breier A, Berg PH, Thakore JH et al (2005) Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatr 162:1879\u20131887","journal-title":"Am J Psychiatr"},{"issue":"5","key":"4763_CR6","first-page":"270","volume":"85","author":"AF Carvalho","year":"2016","unstructured":"Carvalho AF, Sharma MS, Brunoni AR et al (2016) The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother. Psychosomatics 85(5):270\u2013288","journal-title":"Psychosomatics"},{"key":"4763_CR7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1744-859X-10-22","volume":"10","author":"F Chac\u00f3n","year":"2011","unstructured":"Chac\u00f3n F, Mora F, Gerv\u00e1s-R\u00edos A et al (2011) Efficacy of lifestyle interventions in physical health management of patients with severe mental illness. Ann Gen Psychiatry 10:22","journal-title":"Ann Gen Psychiatry"},{"issue":"6","key":"4763_CR8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1185\/03007995.2014.898139","volume":"30","author":"P Chue","year":"2014","unstructured":"Chue P, Mandel FS, Therrien F (2014) The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study. Curr Med Res Opin 30(6):997\u20131005","journal-title":"Curr Med Res Opin"},{"key":"4763_CR9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V et al (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765\u20131773","journal-title":"JAMA"},{"issue":"12","key":"4763_CR10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","volume":"71","author":"CU Correll","year":"2014","unstructured":"Correll CU, Robinson DG, Schooler NR et al (2014) Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry 71(12):1350\u20131363","journal-title":"JAMA Psychiatry"},{"key":"4763_CR11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.schres.2013.04.014","volume":"147","author":"B Crespo-Facorro","year":"2013","unstructured":"Crespo-Facorro B, Ortiz-Garcia d l FV, Mata I et al (2013) Aripiprazole, ziprasidone and quetiapine in the treatment of first-episode non-affective psychosis: a 12-week randomized, flexible-dose, open-label trial. Schizophr Res 147:375\u2013382","journal-title":"Schizophr Res"},{"issue":"2","key":"4763_CR12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00213-013-3241-3","volume":"231","author":"B Crespo-Facorro","year":"2014","unstructured":"Crespo-Facorro B, de la Foz VO, Mata I et al (2014) Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology 231(2):357\u2013366","journal-title":"Psychopharmacology"},{"issue":"2","key":"4763_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40120-016-0050-8","volume":"5","author":"B Crespo-Facorro","year":"2016","unstructured":"Crespo-Facorro B, Pelayo-Teran JM, Mayoral-van Son J (2016) Current data on and clinical insights into the treatment of first episode nonaffective psychosis: a comprehensive review. Neurol Ther 5(2):105\u2013130. https:\/\/doi.org\/10.1007\/s40120-016-0050-8","journal-title":"Neurol Ther"},{"key":"4763_CR14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","volume":"20","author":"DG Daniel","year":"1999","unstructured":"Daniel DG, Zimbroff DL, Potkin SG et al (1999) Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491\u2013505","journal-title":"Neuropsychopharmacology"},{"key":"4763_CR15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M Hert De","year":"2011","unstructured":"De Hert M, Detraux J, vanWinkel R et al (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114\u2013126","journal-title":"Nat Rev Endocrinol"},{"key":"4763_CR16","doi-asserted-by":"crossref","unstructured":"Foley DL and Morley KI (2011) Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 68:609\u2013616","DOI":"10.1001\/archgenpsychiatry.2011.2"},{"issue":"6","key":"4763_CR17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499\u2013502","journal-title":"Clin Chem"},{"issue":"2","key":"4763_CR18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/schbul\/sbp037","volume":"37","author":"KP Grootens","year":"2011","unstructured":"Grootens KP, van Veelen NM, Peuskens J et al (2011) Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull 37(2):352\u2013361","journal-title":"Schizophr Bull"},{"key":"4763_CR19","doi-asserted-by":"crossref","unstructured":"Hjorth\u00f8j C, St\u00fcrup AE, McGrath JJ et al (2017) Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 4(4):295\u2013301","DOI":"10.1016\/S2215-0366(17)30078-0"},{"key":"4763_CR20","doi-asserted-by":"publisher","unstructured":"Jensen KG, Correll CU, Rud\u00e5 D et al (2017) Pretreatment cardiometabolic status in youth with early-onset psychosis: baseline results from the TEA trial. J Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.15m10479","DOI":"10.4088\/JCP.15m10479"},{"issue":"9618","key":"4763_CR21","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H et al (2008) Effectiveness of antipsychotic drugsin first-episode schizophrenia and schizophreniform disorder: an openrandomised clinical trial. Lancet 371(9618):1085\u20131097","journal-title":"Lancet"},{"key":"4763_CR22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR et al (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763\u2013771","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"4763_CR23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/01.pra.0000396061.05269.c8","volume":"17","author":"ON Karayal","year":"2011","unstructured":"Karayal ON, Glue P, Bachinsky M et al (2011) Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract 17(2):100\u2013109","journal-title":"J Psychiatr Pract"},{"key":"4763_CR24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","volume":"22","author":"R Kerwin","year":"2007","unstructured":"Kerwin R, Millet B, Herman E et al (2007) A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 22:433\u2013443","journal-title":"Eur Psychiatry"},{"key":"4763_CR25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","volume":"26","author":"BJ Kinon","year":"2006","unstructured":"Kinon BJ, Lipkovich I, Edwards SB et al (2006) A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 26:157\u2013162","journal-title":"J Clin Psychopharmacol"},{"key":"4763_CR26","volume":"4","author":"K Komossa","year":"2009","unstructured":"Komossa K, Rummel-Kluge C, Hunger H et al (2009) Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 4:CD006627","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4763_CR27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.pnpbp.2010.12.003","volume":"35","author":"SY Lee","year":"2011","unstructured":"Lee SY, Park MH, Patkar AA et al (2011) A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry 35(2):490\u2013496","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"4763_CR28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/JCP.0000000000000594","volume":"36","author":"Q Li","year":"2016","unstructured":"Li Q, Chen D, Liu T et al (2016) Sex differences in body mass index and obesity in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol 36(6):643\u2013648","journal-title":"J Clin Psychopharmacol"},{"key":"4763_CR29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"4763_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"334","author":"O Lingjaerde","year":"1987","unstructured":"Lingjaerde O, Ahlfors UG, Bech P et al (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1\u2013100","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"6","key":"4763_CR31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/cap.2011.0015","volume":"21","author":"L Maayan","year":"2011","unstructured":"Maayan L, Correll CU (2011) Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 21(6):517\u2013535","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"4763_CR32","doi-asserted-by":"crossref","unstructured":"Mackin P, Waton T, Watkinson HM et al (2012) A four-year naturalistic prospective study of cardiometabolic disease in antipsychotic-treated patients. Eur Psychiatry 27(1):50\u20135","DOI":"10.1016\/j.eurpsy.2010.08.011"},{"issue":"1\u20133","key":"4763_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.schres.2016.04.036","volume":"174","author":"A Malla","year":"2016","unstructured":"Malla A, Mustafa S, Rho A et al (2016) Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: a one-year outcome study. Schizophr Res 174(1\u20133):120\u2013125. https:\/\/doi.org\/10.1016\/j.schres.2016.04.036","journal-title":"Schizophr Res"},{"issue":"7","key":"4763_CR34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412\u2013419","journal-title":"Diabetologia"},{"key":"4763_CR35","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jpsychires.2007.05.002","volume":"41","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP, Daniel DG, Carson WH Jr et al (2007) A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg\/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 41:895\u2013905","journal-title":"J Psychiatr Res"},{"issue":"3","key":"4763_CR36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjcard.2005.03.085","volume":"96","author":"T McLaughlin","year":"2005","unstructured":"McLaughlin T, Reaven G, Abbasi F et al (2005) Is there a simple way to identify insulinresistant individuals at increased risk of cardiovascular disease? Am J Cardiol 96(3):399\u2013404","journal-title":"Am J Cardiol"},{"key":"4763_CR37","doi-asserted-by":"crossref","first-page":"e742","DOI":"10.4088\/JCP.10r06802","volume":"73","author":"E Pappadopulos","year":"2012","unstructured":"Pappadopulos E, Newcomer JW, Kolluri S (2012) Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of Pfizer-initiated clinical trials. J Clin Psychiatry 73:e742\u2013e748","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"4763_CR38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/acps.12468","volume":"133","author":"A Parabiaghi","year":"2016","unstructured":"Parabiaghi A, Tettamanti M, D\u2019Avanzo B et al (2016) Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatr Scand 133(1):63\u201375","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"4763_CR39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1751-7893.2008.00074.x","volume":"2","author":"JM Pelayo-Ter\u00e1n","year":"2008","unstructured":"Pelayo-Ter\u00e1n JM, P\u00e9rez-Iglesias R, Ram\u00edrez-Bonilla M et al (2008) Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Early Interv Psychiatry 2(3):178\u2013187","journal-title":"Early Interv Psychiatry"},{"issue":"11","key":"4763_CR40","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.4088\/JCP.v68n1113","volume":"68","author":"R Perez-Iglesias","year":"2007","unstructured":"Perez-Iglesias R, Crespo-Facorro B, Amado JA et al (2007) A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 68(11):1733\u20131740","journal-title":"J Clin Psychiatry"},{"issue":"1\u20133","key":"4763_CR41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","volume":"99","author":"R Perez-Iglesias","year":"2008","unstructured":"Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O et al (2008) Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-na\u00efve population. Schizophr Res 99(1\u20133):13\u201322","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"4763_CR42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2008.09.028","volume":"107","author":"R Perez-Iglesias","year":"2009","unstructured":"Perez-Iglesias R, Mata I, Pelayo-Teran JM et al (2009) Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-na\u00efve population. Schizophr Res 107(2\u20133):115\u2013121","journal-title":"Schizophr Res"},{"issue":"1","key":"4763_CR43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2014.07.045","volume":"159","author":"R P\u00e9rez-Iglesias","year":"2014","unstructured":"P\u00e9rez-Iglesias R, Ortiz-Garcia de la Foz V, Mart\u00ednez Garc\u00eda O et al (2014a) Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophr Res 159(1):90\u201394","journal-title":"Schizophr Res"},{"issue":"1","key":"4763_CR44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S1461145713001053","volume":"17","author":"R P\u00e9rez-Iglesias","year":"2014","unstructured":"P\u00e9rez-Iglesias R, Mart\u00ednez-Garc\u00eda O, Pardo-Garcia G et al (2014b) Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol 17(1):41\u201351","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"4763_CR45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","volume":"74","author":"T Pillinger","year":"2017","unstructured":"Pillinger T, Beck K, Gobjila C et al (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74(3):261\u2013269","journal-title":"JAMA Psychiatry"},{"key":"4763_CR46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S et al (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225\u2013233","journal-title":"Schizophr Res"},{"key":"4763_CR47","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4088\/JCP.v68n0308","volume":"68","author":"RD Spurling","year":"2007","unstructured":"Spurling RD, Lamberti JS, Olsen D et al (2007) Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 68:406\u2013409","journal-title":"J Clin Psychiatry"},{"key":"4763_CR48","doi-asserted-by":"crossref","unstructured":"Stahl SM, Mignon L, Meyer JM (2009) Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 119(3):171\u20139","DOI":"10.1111\/j.1600-0447.2008.01334.x"},{"key":"4763_CR49","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP et al (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatr 163:611\u2013622","journal-title":"Am J Psychiatr"},{"key":"4763_CR50","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","volume":"168","author":"TS Stroup","year":"2011","unstructured":"Stroup TS, McEvoy JP, Ring KD et al (2011) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168:947\u2013956","journal-title":"Am J Psychiatry"},{"key":"4763_CR51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1440-1819.2009.02036.x","volume":"64","author":"H Takeuchi","year":"2010","unstructured":"Takeuchi H, Uchida H, Suzuki T et al (2010) Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry. Clin Neurosci 64:104\u2013106","journal-title":"Clin Neurosci"},{"issue":"17","key":"4763_CR52","first-page":"30126","volume":"pii: S0920-9964","author":"D Zhai","year":"2017","unstructured":"Zhai D, Lang Y, Feng Y et al (2017) Early onset of cardiometabolic risk factor profiles in drug na\u00efve adolescents and young adults with first-episode schizophrenia. Schizophr Res pii: S0920-9964(17):30126\u201330123","journal-title":"Schizophr Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4763-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T15:10:57Z","timestamp":1603206657000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["4763"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4763-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]}}}